Cargando…
S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428345/ http://dx.doi.org/10.1097/01.HS9.0000967440.83852.70 |
| _version_ | 1785090446365556736 |
|---|---|
| author | Miguel Bergua Burgues, Juan Rodríguez-Veiga, Rebeca Cano Ferri, Isabel Vall-Llovera Calmet, Ferran Garcia-Guiñon, Antonio Gomez Espuch, Joaquin Colorado, Mercedes Casas-Avilés, Ignacio Esteve, Jordi Sampol, Antonia Victoria Verdugo, Maria Ramos, Fernando Valero, Marta Gloria Acuña Cruz, Evelyn Boluda, Blanca Torres Miñana, Laura Martinez-Lopez, Joaquín Barragan, Eva Ayala Diaz, Rosa Martinez-Cuadrón, David Montesinos, Pau |
| author_facet | Miguel Bergua Burgues, Juan Rodríguez-Veiga, Rebeca Cano Ferri, Isabel Vall-Llovera Calmet, Ferran Garcia-Guiñon, Antonio Gomez Espuch, Joaquin Colorado, Mercedes Casas-Avilés, Ignacio Esteve, Jordi Sampol, Antonia Victoria Verdugo, Maria Ramos, Fernando Valero, Marta Gloria Acuña Cruz, Evelyn Boluda, Blanca Torres Miñana, Laura Martinez-Lopez, Joaquín Barragan, Eva Ayala Diaz, Rosa Martinez-Cuadrón, David Montesinos, Pau |
| author_sort | Miguel Bergua Burgues, Juan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428345 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283452023-08-17 S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB Miguel Bergua Burgues, Juan Rodríguez-Veiga, Rebeca Cano Ferri, Isabel Vall-Llovera Calmet, Ferran Garcia-Guiñon, Antonio Gomez Espuch, Joaquin Colorado, Mercedes Casas-Avilés, Ignacio Esteve, Jordi Sampol, Antonia Victoria Verdugo, Maria Ramos, Fernando Valero, Marta Gloria Acuña Cruz, Evelyn Boluda, Blanca Torres Miñana, Laura Martinez-Lopez, Joaquín Barragan, Eva Ayala Diaz, Rosa Martinez-Cuadrón, David Montesinos, Pau Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428345/ http://dx.doi.org/10.1097/01.HS9.0000967440.83852.70 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Miguel Bergua Burgues, Juan Rodríguez-Veiga, Rebeca Cano Ferri, Isabel Vall-Llovera Calmet, Ferran Garcia-Guiñon, Antonio Gomez Espuch, Joaquin Colorado, Mercedes Casas-Avilés, Ignacio Esteve, Jordi Sampol, Antonia Victoria Verdugo, Maria Ramos, Fernando Valero, Marta Gloria Acuña Cruz, Evelyn Boluda, Blanca Torres Miñana, Laura Martinez-Lopez, Joaquín Barragan, Eva Ayala Diaz, Rosa Martinez-Cuadrón, David Montesinos, Pau S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title | S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title_full | S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title_fullStr | S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title_full_unstemmed | S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title_short | S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB |
| title_sort | s132: updated results of ven-a-qui study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit aml patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428345/ http://dx.doi.org/10.1097/01.HS9.0000967440.83852.70 |
| work_keys_str_mv | AT miguelberguaburguesjuan s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT rodriguezveigarebeca s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT canoferriisabel s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT valllloveracalmetferran s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT garciaguinonantonio s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT gomezespuchjoaquin s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT coloradomercedes s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT casasavilesignacio s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT estevejordi s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT sampolantonia s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT victoriaverdugomaria s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT ramosfernando s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT valeromarta s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT gloriaacunacruzevelyn s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT boludablanca s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT torresminanalaura s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT martinezlopezjoaquin s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT barraganeva s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT ayaladiazrosa s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT martinezcuadrondavid s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib AT montesinospau s132updatedresultsofvenaquistudyaphase12trialtoassessthesafetyandefficacyoftripletsfornewlydiagnosedunfitamlpatientsazacitidineorlowdosecytarabinewithvenetoclaxandquizartinib |